SCHEMBL3019075

SCHEMBL3019075

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.42
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH3A1 P30838 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
CHRM5 P08912 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651949 0.93 MAPT (0.44) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3013526 0.92 LMNA (0.47) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3018807 0.91 TP53 (0.41) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3016841 0.91 LMNA (0.39) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3010728 0.90 LMNA (0.40) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3011747 0.89 MAPT (0.47) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3008696 0.89 TRPV4 (0.47) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3011395 0.89 ALDH1A1 (0.49) LMNAMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3010327 0.89 MEN1 (0.43) TP53LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3002366 0.89 LMNA (0.39) TP53LMNAMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TP53 2880/4885LMNA 80/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.